Retraction to: Extranuclear ERα is associated with regression of T47D PKCα-overexpressing, tamoxifen-resistant breast cancer. [Mol Cancer. 12, (2013) (34)] DOI: 10.1186/1476-4598-12-34

Bethany Perez White, Mary Ellen Molloy, Huiping Zhao, Yiyun Zhang, Debra A. Tonetti*

*Corresponding author for this work

Research output: Contribution to journalComment/debatepeer-review

Abstract

This article [1] has been retracted by the authors after they discovered an error in the data. The authors recently performed Short Tandem Repeat (STR) analysis on all of their cell lines and discovered that the cell clone T47D:A18/PKCa is in fact MCF-7/PKCa. They have verified this using next generation sequencing of the p53 mutation that is a hallmark of T47D cells. All other cell lines reported in this article are as originally described. As a result of this error, parts of the article are inaccurate which affects the article's conclusions. The authors will be given the opportunity to resubmit their corrected data.

Original languageEnglish (US)
Article number121
JournalMolecular Cancer
Volume16
Issue number1
DOIs
StatePublished - Jul 17 2017

ASJC Scopus subject areas

  • Molecular Medicine
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Retraction to: Extranuclear ERα is associated with regression of T47D PKCα-overexpressing, tamoxifen-resistant breast cancer. [Mol Cancer. 12, (2013) (34)] DOI: 10.1186/1476-4598-12-34'. Together they form a unique fingerprint.

Cite this